future of protein production with plates with healthy food and protein

Food as medicine: A patent perspective

April 28, 2026

Although my New Year’s resolutions are a distant memory, like many I have taken 2026 as an opportunity to focus on health. This, too, is a growing trend in the alternative protein space. The reasons are clear: while price remains challenging and consumer preferences fickle, health claims are a tangible and actionable focus for product developers. However, while these can provide a competitive edge, locking in this protection and securing a market position through IP can be challenging.
When navigating the gray zone between food and medicine, a winning strategy must grapple with the specific nutritional and regulatory challenges involved.

The trend for protein remains strong, as consumers look for increased satiety and muscle-building potential in their meals. However, recent trends are turning away
from crude percentages and looking deeper into the nutritional makeup of protein sources. ‘Amino acid quality’, a measure of the availability of all nine essential amino acids and their bioavailability, is of increasing interest. As an IP professional, this is a welcome turn. Foods with improved amino acid quality are ideal candidates for strong patent portfolios. Not only can they be clearly defined, allowing distinction from known foods, but they also offer a clear health benefit that supports robust protection. Combining patent protection with trade secrets – the ‘secret recipe’ or know-how through which the profiles are obtained – can provide a formidable moat to support a price premium for a high-end health product.

When navigating the gray zone between food and medicine, a winning strategy must grapple with the specific nutritional and regulatory challenges involved

So-called ‘functional foods’ and nutraceuticals go beyond contributing to a healthy lifestyle and make concrete health claims. Whether promoting skin health
or reversing diabetes, they are among the fastest-growing segments of the food industry, driven by increased public awareness of the link between diet and health. However, for ‘food as medicine’, the IP situation can be neither fish nor fowl. Although there is an extensive framework for obtaining patents on medicines, these can remain out of reach. Before the IP offices of most countries, no distinction is drawn between foods and medicines. Thus, to obtain strong protection, it is often desirable to direct patents toward foodstuffs for use in treatment – a so-called ‘medical use’ claim. As case law has developed for pharmaceutical products, the evidence required to support these claims can be challenging, especially for longitudinal and holistic benefits such as gut health.

Yet the main challenge in this legal approach is that it often conflicts with regulatory frameworks for functional foods. For example, the EU prohibits labeling foods with claims that they prevent, treat or cure human diseases. This results in patent claims that provide protection only if products are marketed for these prohibited activities, offering little recourse against competitors making health claims. Instead, a bespoke IP strategy is required, focusing on disease prevention or mechanism of action, tailored to the specific food.

A new horizon in foods – and one where alternative proteins have significant opportunity – is in products tailored for GLP-1 receptor agonist therapies such as semaglutide. These ‘weight loss’ drugs reduce appetite and improve glycaemic control but, to maximize their impact and avoid side effects such as nausea and muscle loss, patients are advised to follow diets high in protein and fiber. Given reduced intake, this places a premium on nutrient density and digestibility.

An interesting challenge will be how best to secure these market positions. IP strategies used for ‘combination therapies’ are unlikely to be effective here, as they rely on regulatory pathways and healthcare models not applicable to food. Relying on nutrient profiles, as with amino acid quality, may be a solution, particularly where innovation lies in improving efficacy or digestibility in a non-obvious way.

Moreover, this segment poses a branding challenge. Marketing products for use with named drugs may be blocked by pharmaceutical companies holding trademarks around those names. Even generic labels such as ‘GLP-1 friendly’ could create liability and need careful consideration. That said, as demand for GLP-1 therapies rises, companies that find a way to protect and market their foods to this sector will be well placed to tap into a growing, profitable market.

Andrew Tindall is a Patent Director and patent attorney at HGF, based in London. He has a special interest in the technologies shaping the futures of food science, having spent his career working with alternative protein clients ranging from startups to investors and multinationals. This article is republished from the Q1 2026 edition of Protein Production Technology International, the industry's leading resource for alternative proteins. To subscribe to all future editions, please click here

If you have any questions or would like to get in touch with us, please email info@futureofproteinproduction.com

About the Speaker

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.